09.08.11
A recent survey conducted by InterHealth Nutraceuticals shows more than 88% of diabetes educators said results from a double-blind, placebo-controlled study supports the conclusion that Zychrome is better than chromium picolinate for insulin management.
The survey of diabetes educators was taken at the American Association of Diabetes Educators (AADE) Annual Meeting & Exhibition. AADE attendees surveyed reviewed preliminary results from a randomized, double-blind, placebo-controlled study comparing InterHealth’s next generation chromium, Zychrome, to chromium picolinate for insulin function in people with type 2 diabetes. Preliminary results of the comparative study demonstrate that Zychrome significantly improved insulin function and impacted insulin levels by 30% compared to baseline.
More than 70% said they would recommend Zychrome for insulin management over chromium picolinate. “Many diabetes educators were very excited about the research and eager to learn more about Zychrome,” said Francis Lau, PhD, FACN, lead scientist for InterHealth Nutraceuticals who also administered the survey.
The survey of diabetes educators was taken at the American Association of Diabetes Educators (AADE) Annual Meeting & Exhibition. AADE attendees surveyed reviewed preliminary results from a randomized, double-blind, placebo-controlled study comparing InterHealth’s next generation chromium, Zychrome, to chromium picolinate for insulin function in people with type 2 diabetes. Preliminary results of the comparative study demonstrate that Zychrome significantly improved insulin function and impacted insulin levels by 30% compared to baseline.
More than 70% said they would recommend Zychrome for insulin management over chromium picolinate. “Many diabetes educators were very excited about the research and eager to learn more about Zychrome,” said Francis Lau, PhD, FACN, lead scientist for InterHealth Nutraceuticals who also administered the survey.